ReproCELL Incorporated (TYO:4978)
192.00
+15.00 (8.47%)
Mar 6, 2026, 3:30 PM JST
ReproCELL Revenue
ReproCELL had revenue of 635.00M JPY in the quarter ending December 31, 2025, a decrease of -15.11%. This brings the company's revenue in the last twelve months to 2.52B, down -7.32% year-over-year. In the fiscal year ending March 31, 2025, ReproCELL had annual revenue of 2.98B with 22.75% growth.
Revenue (ttm)
2.52B
Revenue Growth
-7.32%
P/S Ratio
7.22
Revenue / Employee
25.44M
Employees
99
Market Cap
18.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.98B | 552.00M | 22.75% |
| Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
| Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
| Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
| Mar 31, 2021 | 1.29B | 87.00M | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 7.06B |
| RaQualia Pharma | 3.98B |
| Immuno-Biological Laboratories | 1.03B |
| Stella Pharma | 968.00M |
| AnGes | 874.00M |
| CellSeed | 161.00M |
| Nano Holdings | 155.00M |
| Renascience | 107.00M |